GFM
KRYS icon

GF Fund Management’s Krystal Biotech KRYS Stock Holding History

GF Fund Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Sell
620
-31
-5% -$9.26K ﹤0.01% 262
2026
Q1 		$168K Buy
651
+82
+14% +$21.8K ﹤0.01% 299
2025
Q4 		$140K Sell
569
-54
-9% -$11.4K ﹤0.01% 319
2025
Q3 		$110K Sell
623
-113
-15% -$16.9K ﹤0.01% 329
2025
Q2 		$101K Hold
736
– – ﹤0.01% 365
2025
Q1 		$133K Buy
736
+132
+22% +$22.2K ﹤0.01% 347
2024
Q4 		$94.6K Buy
+604
New +$107K ﹤0.01% 335

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GF Fund Management's KRYS Position: Q2 2026 in Review

GF Fund Management reduced its Krystal Biotech (KRYS) stake by 4.8% in Q2 2026, selling an estimated $9.26K and leaving 620 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #262.

GF Fund Management first reported a position in KRYS in Q4 2024 and has held it in 7 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • GF Fund Management held 620 shares of Krystal Biotech worth $230K as of Q2 2026.
  • GF Fund Management sold 31 Krystal Biotech shares in Q2 2026, an estimated $9.26K.
  • Krystal Biotech made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #262 holding.
  • GF Fund Management first reported a position in Krystal Biotech in Q4 2024 and has held it in 7 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.